[20]LuS, WuL, JianH, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second i...
引言 肺癌中最常见的类型是非小细胞肺癌（Non-small Cell Lung Cancer, NSCLC），占所有肺癌病例的80%至85%，由于其高发病率及多数患者确诊时已为晚期，使得治疗难度显著增加。近年来，随着医学技术的不断进步，NSCLC的治疗手段日益多样化，涵盖了手术、化疗、放疗、靶向治疗及免疫治疗等多种方法。本文将综述当前肿瘤...
非鳞非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌的一种常见类型。与鳞状细胞肺癌相比,NSCLC发展速度较慢,但其治疗较复杂。本文将介绍NSCLC的原因、症状、诊断和治疗方法。 NSCLC的主要原因是吸烟,尤其是长期吸烟。吸入的烟雾中的有害物质会损害肺部细胞的DNA,导致细胞异常增殖和癌症发生。此外,暴露在污染...
unresectable,stage ll non-small-cell lung cancer in China (GEMSTONE-301): Interim results of a randomised,double-blind,multicentre, phase 3 trial. LancetOncol.2022.23(2):209-219.
1. 晚期非小细胞肺癌 ...春碱(vinorlbine VIL)同步应用于局部晚期非小细胞肺癌(Non Small Cell Lung Cancer NSCLC)的放射治疗(Radiotherap…cdmd.cnki.com.cn|基于1 个网页 例句 释义: 全部,晚期非小细胞肺癌 更多例句筛选 1. Thoracic radiotherapy has been a key component of local treatment for the pat...
Lung cancers are generally divided into two main categories: small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancers.
参考文献 1. Horvath L, Thienpont B,Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-smallcell lung cancer (NSCLC) - novel approaches and future outlook. Mol Cancer.2020 Sep 11;19(1):141. doi: 10.1186/s12943-020-01260-z. PMID: 32917214; PMCID:PMC7488475. ...
基于上述结果,该药于2006 年被美国食品药品监督管理局(FDA) 批准联合标准化疗一线治疗进展期非鳞非小细胞肺癌(non-squamousnon-small cell lung cancer,nsNSCL)。 BEYOND研究[4]:国内一项随机、双盲、安慰剂对照、多中心Ⅲ期研究。BEYOND是首个专门针对贝伐单抗在中国nsNSCLC人群疗效的临床研究,该研究纳入276例局部晚...
1.Breakthrough in targeted therapy for non-small cell lung cancer. 2.Overcoming therapy resistance in EGFR-mutant lung cancer. 3.Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. FYI:总结生物医药更多知识点,敬请关注公众平台「佰傲谷BioValley」 部分图源网络...
[5]. West H, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019...